Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2
Abstract Objective This post hoc analysis of the SELECT-PsA 2 study evaluated long-term efficacy and safety of upadacitinib 15 mg once daily in patients with psoriatic arthritis (PsA) and exposure to one prior tumour necrosis factor inhibitor (TNFi). Methods Patients were randomised to upadacitinib 15 mg once daily or...